Cytokinetics, Incorporated (CYTK) Price Prediction 2026–2050

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.

In addition, the company is involved in developing Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics operates in the Healthcare sector, pursuing therapies that target cardiac muscle function and related heart conditions through a portfolio of drug candidates and ongoing clinical development programs. The company’s focus on muscle activators and inhibitors positions it in a niche area within cardiovascular therapeutics, with multiple candidates at various stages of development and clinical testing.

CYTK is currently priced at $76.94, with a market cap of $10.45B, and is ranked 891. These fundamentals place the stock among mid-sized healthcare players with a developed portfolio in cardiac myosin inhibitors and related therapies.

The forecast indicates a mixed but ultimately bullish price trajectory after a neutral start in 2026. The 2026 forecast shows a min of $59.58, an avg of $76.94, and a max of $112.99 (ROI 0, sentiment NEUTRAL). From 2027 onward, the outlook turns bullish, with the avg rising through the decade and into the 2030s, reaching $127.81 by 2030 and climbing to $843.91 by 2050.

Notable year-by-year milestones include 2027 avg $98.55 and 2040 avg $371.25, with 2050 forecast at $843.91, accompanied by increasingly strong ROI figures.

Overall, the price outlook suggests substantial long-term upside with elevated risk and volatility typical of biotech equities, while acknowledging that these figures are forecasts and not guarantees.

The multi-year forecast shows a clear bullish trend after 2026, with meaningful upside through 2030 and beyond. The 2030 average price is $127.81, with a min of $95.96 and a max of $183.07, corresponding to a 66.1% ROI and a bullish sentiment.

In 2040, the average forecast rises to $371.25, with a min of $244.23 and a max of $610.66, yielding a 382.5% ROI and continued bullish sentiment. By 2050, the average is projected to $843.91, with a min of $501.87 and a max of $1,509.98, and a remarkable 996.8% ROI, still categorized as bullish.

These are estimates expressed as potential outcomes and carry inherent uncertainty. While the trajectory points to substantial long-term upside, investors should consider the inherent risks and volatility associated with biotech equities, and treat these figures as directional rather than guaranteed outcomes.